<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Tang XH</submitter><funding>NIDDK NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>101331</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8626588</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>297(6)</volume><pubmed_abstract>Nonalcohol-associated fatty liver disease (NAFLD) is characterized by excessive hepatic accumulation of fat that can progress to steatohepatitis, and currently, therapeutic options are limited. Using a high-fat diet (HFD) mouse model of NAFLD, we determined the effects of the synthetic retinoid, AC261066, a selective retinoic acid receptor β2 (RARβ2) agonist, on the global liver transcriptomes and metabolomes of mice with dietary-induced obesity (DIO) using genome-wide RNA-seq and untargeted metabolomics. We found that AC261066 limits mRNA increases in several presumptive NAFLD driver genes, including Pklr, Fasn, Thrsp, and Chchd6. Importantly, AC261066 limits the increases in the transcript and protein levels of KHK, a key enzyme for fructose metabolism, and causes multiple changes in liv</pubmed_abstract><journal>The Journal of biological chemistry</journal><pubmed_title>A retinoic acid receptor β2 agonist attenuates transcriptome and metabolome changes underlying nonalcohol-associated fatty liver disease.</pubmed_title><pmcid>PMC8626588</pmcid><funding_grant_id>T32 CA062948</funding_grant_id><funding_grant_id>R01 DK113088</funding_grant_id><pubmed_authors>Rappa A</pubmed_authors><pubmed_authors>Gross SS</pubmed_authors><pubmed_authors>Zhang T</pubmed_authors><pubmed_authors>Tang XH</pubmed_authors><pubmed_authors>Melis M</pubmed_authors><pubmed_authors>Lu C</pubmed_authors><pubmed_authors>Jessurun J</pubmed_authors><pubmed_authors>Gudas LJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>A retinoic acid receptor β2 agonist attenuates transcriptome and metabolome changes underlying nonalcohol-associated fatty liver disease.</name><description>Nonalcohol-associated fatty liver disease (NAFLD) is characterized by excessive hepatic accumulation of fat that can progress to steatohepatitis, and currently, therapeutic options are limited. Using a high-fat diet (HFD) mouse model of NAFLD, we determined the effects of the synthetic retinoid, AC261066, a selective retinoic acid receptor β2 (RARβ2) agonist, on the global liver transcriptomes and metabolomes of mice with dietary-induced obesity (DIO) using genome-wide RNA-seq and untargeted metabolomics. We found that AC261066 limits mRNA increases in several presumptive NAFLD driver genes, including Pklr, Fasn, Thrsp, and Chchd6. Importantly, AC261066 limits the increases in the transcript and protein levels of KHK, a key enzyme for fructose metabolism, and causes multiple changes in liv</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Dec</publication><modification>2026-05-08T20:42:11.573Z</modification><creation>2022-02-11T13:35:19.117Z</creation></dates><accession>S-EPMC8626588</accession><cross_references><pubmed>34688661</pubmed><doi>10.1016/j.jbc.2021.101331</doi></cross_references></HashMap>